A Bullous Eruption following the Pfizer-BioNTech COVID-19 vaccination.

On December 2nd, 2020 the Medicines and Healthcare products Regulatory Agency (MHRA) authorized use of a modRNA - nucleoside modified messenger RNA (mRNA) COVID-19 vaccine; Pfizer- BioNTech. Prior to this, no mRNA vaccines had been authorized for use in humans1 . As of June 2021, 66 million COVID-19 vaccinations have been administered within the UK2 . Currently approved vaccines for use in the UK include Pfizer/BioNTech, Oxford/AstraZeneca, and Moderna variants. An ongoing multinational randomised controlled trial assessing the safety of the Pfizer-BioNTech vaccine reported few localized cutaneous reactions at the injection site, but no significant adverse cutaneous reactions. The data from this study suggested a two-dose regimen of the Pfizer vaccine was safe and effective in 95% of cases3 .